BVXV
Price:
$1.36
Market Cap:
$4.97M
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.[Read more]
Industry
Biotechnology
IPO Date
2015-05-12
Stock Exchange
NASDAQ
Ticker
BVXV
According to BiondVax Pharmaceuticals Ltd.’s latest financial reports and current stock price. The company's current Enterprise Value is 22.07M. This represents a change of -100.00% compared to the average of 558.05B of the last 4 quarters.
The mean historical Enterprise Value of BiondVax Pharmaceuticals Ltd. over the last ten years is 223.29B. The current 22.07M Enterprise Value has changed -99.01% with respect to the historical average. Over the past ten years (40 quarters), BVXV's Enterprise Value was at its highest in in the December 2022 quarter at 2.23T. The Enterprise Value was at its lowest in in the December 2013 quarter at -17863000.00.
Average
223.29B
Median
86.00M
Minimum
7.24M
Maximum
2.23T
Discovering the peaks and valleys of BiondVax Pharmaceuticals Ltd. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.88%
Maximum Annual Enterprise Value = 2.23T
Minimum Annual Increase = -86.58%
Minimum Annual Enterprise Value = 7.24M
Year | Enterprise Value | Change |
---|---|---|
2022 | 2.23T | 1.88% |
2021 | 118.66M | 0.55% |
2020 | 118.02M | -63.19% |
2019 | 320.61M | 164.53% |
2018 | 121.20M | 388.92% |
2017 | 24.79M | -10.76% |
2016 | 27.78M | 283.50% |
2015 | 7.24M | -86.58% |
2014 | 53.97M | 39.39% |
2013 | 38.72M | -22.42% |
The current Enterprise Value of BiondVax Pharmaceuticals Ltd. (BVXV) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
744.10B
5-year avg
446.55B
10-year avg
223.29B
BiondVax Pharmaceuticals Ltd.’s Enterprise Value is greater than First Wave BioPharma, Inc. (9.55M), greater than Salarius Pharmaceuticals, Inc. (-1183141.00), less than SAB Biotherapeutics, Inc. (25.39M), greater than Vaccinex, Inc. (8.95M), greater than GeoVax Labs, Inc. (13.84M), less than Molecular Partners AG (57.69M), less than Mineralys Therapeutics, Inc. (603.45M), greater than AN2 Therapeutics, Inc. (5.46M), less than Pharvaris N.V. (844.35M), less than PepGen Inc. (174.61M), greater than Can-Fite BioPharma Ltd. (10.51M), less than Oramed Pharmaceuticals Inc. (167.97M), less than MediWound Ltd. (201.88M), less than BioLineRx Ltd. (59.04M), greater than Surrozen, Inc. (2.49M), less than Armata Pharmaceuticals, Inc. (204.77M), greater than Pasithea Therapeutics Corp. (-4187996.00), greater than Oncternal Therapeutics, Inc. (-1766718.00), greater than Aditxt, Inc. (12.23M), greater than Adial Pharmaceuticals, Inc. (3.15M), greater than TransCode Therapeutics, Inc. (5.76M), less than Reviva Pharmaceuticals Holdings, Inc. (28.64M), greater than Avenue Therapeutics, Inc. (-1770008.00),
Company | Enterprise Value | Market cap |
---|---|---|
9.55M | $5.99M | |
-1183141.00 | $2.09M | |
25.39M | $37.29M | |
8.95M | $9.06M | |
13.84M | $15.26M | |
57.69M | $247.30M | |
603.45M | $671.31M | |
5.46M | $32.23M | |
844.35M | $1.29B | |
174.61M | $221.28M | |
10.51M | $15.23M | |
167.97M | $97.44M | |
201.88M | $197.82M | |
59.04M | $37.41M | |
2.49M | $38.09M | |
204.77M | $85.03M | |
-4187996.00 | $3.78M | |
-1766718.00 | $4.38M | |
12.23M | $4.28M | |
3.15M | $6.44M | |
5.76M | $8.89M | |
28.64M | $33.39M | |
-1770008.00 | $3.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BiondVax Pharmaceuticals Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BiondVax Pharmaceuticals Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BiondVax Pharmaceuticals Ltd.'s Enterprise Value?
What is the highest Enterprise Value for BiondVax Pharmaceuticals Ltd. (BVXV)?
What is the 3-year average Enterprise Value for BiondVax Pharmaceuticals Ltd. (BVXV)?
What is the 5-year average Enterprise Value for BiondVax Pharmaceuticals Ltd. (BVXV)?
How does the current Enterprise Value for BiondVax Pharmaceuticals Ltd. (BVXV) compare to its historical average?